Search Results

You are looking at 31 - 40 of 1,029 items for :

  • "community" x
  • Refine by Access: Content accessible to Me x
Clear All
Full access

NCCN Task Force Report: Specialty Pharmacy

Rowena N. Schwartz, Kirby J. Eng, Deborah A. Frieze, Tracy K. Gosselin, Niesha Griffith, Amy Hatfield Seung, Jennifer M. Hinkel, Philip E. Johnson, Shirley A. Johnson, Edward C. Li, Audrea Hotsko Szabatura, and Michael K. Wong

standard and may include models such as mail-order distribution (the traditional model for specialty pharmacy) or distribution from a community pharmacy. One historic feature of specialty pharmacy is the focus on diseases that are chronic and low

Full access

CGE22-100: Community Oncologists’ Current and Future Patterns of Germline Testing for Patients With Early-Stage Breast Cancer

Dewilka Simons, Yolaine Jeune-Smith, Bruce Feinberg, Stephanie Fortier, and Ajeet Gajra

surveyed community hematologists/oncologists (cH/O) on their perceptions of the OlympiA trial data and the potential impact on their BRCA 1/2 testing habits in patients with early-stage BC. Methods : Between June and October 2021, practicing U.S. cH/O were

Full access

Risk of Febrile Neutropenia Associated With Select Myelosuppressive Chemotherapy Regimens in a Large Community-Based Oncology Practice

Yanli Li, Leila Family, Su-Jau Yang, Zandra Klippel, John H. Page, and Chun Chao

strengths. Data were used from a large community-based population of patients with cancer; therefore, the findings may better reflect FN risks in the real-world setting. The comprehensive clinical databases at KPSC allowed for detailed characterizations of

Full access

BPI22-015: Analysis of NCCN-Preferred Treatment Regimen Ordering via an EHR-Embedded Decision Support Tool in a Community Oncology Practice

Jonas M Congelli, Rebecca Maniago, Stephanie Jou, Janet Donegan, and Ivy Altomare

documentation of NCCN Guideline concordant and NCCN preferred treatment regimens. We assessed patterns of concordant, preferred and non-preferred treatment regimen ordering at one large multi-site community practice. Methods : We reviewed all treatment orders

Full access

EPR22-113: Awareness, Utilization, and NCCN Guideline-Adherence to Breast Cancer Risk Management Behavior Among a Community-Based Sample of High-Risk Women

Rachel J Meadows, Anna Muraveva, Christina Bijou, Kate Shane-Carson, Coralia Balasca, Celia E Wills, Lisa D Yee, Electra D Paskett, and Tasleem J Padamsee

, community-based sample. Methods : This study uses data (collected Oct 2018–Aug 2019) from a survey that included measures of risk-management behavior, potential correlates, and information necessary to determine lifetime BC risk. Eligible participants were

Full access

HSR22-167: Burden of Myelosuppression Among Patients With Extensive-Stage Small Cell Lung Cancer Treated With Chemotherapy in a Community Oncology Setting

Jeffrey Scott, Dean Slack, Lindsay Gingras, Marc Chioda, and Huan Huang

study aimed to assess the prevalence of HAEs and associated health care resource utilization among patients receiving chemotherapy for ES-SCLC in the community oncology setting. Methods : Adult patients with ES-SCLC included in the Integra Connect

Full access

HSR21-047: Tumor Lysis Syndrome Risk Analysis in a US Community Oncology Setting: A Retrospective Observational Study in Integra Connect Network

Kaustav Chatterjee, Edward Drea, Robert Smith, Mei Xue, Hunter Lambert, Jeffrey Scott, Sorena Nadaf, Simon Blanc, Prateesh Varughese, and John Verniero

following chemotherapy [1] . However, no real-world data has been published that quantifies TLS risk factors by cancer type. Methods: The Integra database of 17 community oncology accounts was queried for patients ≥18 years of age having a TLS ICD10 code

Full access

HSR23-111: Real-World EGFR Testing in Patients With Surgically Resected Stage I-III Non–Small Cell Lung Cancer (NSCLC) in US Community Oncology Practices

Anne Shah, Jon Apple, Joanne Willey, Michael Ayars, Daniel Simmons, Dana Nickleach, Ganiat Mumuney, Manish Patel, and Kristen Brunskill

25 Nov 2020 to encourage testing for EGFR mutations in eligible patients with resectable NSCLC. This study evaluated real-world testing for EGFR, including the impact of guideline changes (before vs after 25 Nov 2020) on testing in the US community

Full access

BPI22-010: Applying FRAME to Code Modifications to a Community-Based Educational Intervention and Lung Cancer Screening Protocols Amidst the Covid-19 Pandemic

Sydney Beache, Aimee James, Graham Colditz, and Courtney Harriss

Background : While lung cancer is a leading cause of death in the U.S., annual screening rates with low-dose Computed Tomography (LDCT) among eligible candidates remain low at 12.7%. The WUSTL research group began a community intervention to

Full access

Adjuvant Chemotherapy Regimens for Breast Cancer

Data adapted from Bergstrom et al. 1 Data based on reporting from 750 community oncology practices in the United States to McKesson Specialty Care Solutions. Adjuvant chemotherapy for breast cancer has evolved over several decades